Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week High – Here’s Why

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $19.53 and last traded at $19.44, with a volume of 356083 shares. The stock had previously closed at $18.28.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analysts currently assign Cullinan Therapeutics an average rating of “Moderate Buy”, indicating generally favorable sentiment toward the biotechnology company’s pipeline and longer-term prospects. Cullinan Therapeutics Receives Average Rating of Moderate Buy from Analysts
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $30 price target for CGEM, implying substantial upside from the stock’s recent level around $19.60. The firm’s published estimates show expected losses narrowing modestly during 2027, although the company is still projected to remain unprofitable. HC Wainwright analyst estimates for Cullinan Therapeutics
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio. Because the data showed no measurable short position and an unusable percentage change, it provides little meaningful indication of investor positioning or likely trading pressure.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $3.53 per share from a $3.42 loss, and reduced its Q3 2026 forecast to a $0.90 loss from $0.87. The firm also cut its Q4 2026 estimate to a $0.93 loss from $0.90, signaling somewhat higher expected near-term expenses.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a report on Monday, June 8th. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, June 11th. Finally, BTIG Research lifted their target price on shares of Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cullinan Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.14.

Cullinan Therapeutics Price Performance

The business has a 50 day moving average price of $16.81 and a 200 day moving average price of $14.99. The stock has a market capitalization of $1.26 billion, a PE ratio of -6.32 and a beta of 0.01.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, equities analysts expect that Cullinan Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the transaction, the insider directly owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. The trade was a 4.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd bought a new position in Cullinan Therapeutics in the 1st quarter valued at approximately $163,000. Jane Street Group LLC raised its stake in shares of Cullinan Therapeutics by 145.9% in the first quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock worth $260,000 after purchasing an additional 109,413 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Cullinan Therapeutics in the first quarter worth $618,000. Creative Planning lifted its holdings in shares of Cullinan Therapeutics by 222.2% during the second quarter. Creative Planning now owns 41,723 shares of the company’s stock valued at $314,000 after purchasing an additional 28,773 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Cullinan Therapeutics by 122.9% during the second quarter. JPMorgan Chase & Co. now owns 97,069 shares of the company’s stock valued at $731,000 after purchasing an additional 53,522 shares in the last quarter. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.